Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics / Rapid and point-of-care molecular testing for acute-care decisions

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Rapid and point-of-care molecular testing for acute-care decisions

Compact, cartridge-based molecular systems used at the point of care or near the bedside (emergency departments, urgent care, intensive care, outpatient clinics) to return a syndromic result in minutes and support immediate isolation, antibiotic or admission decisions. Job to be done: shorten time-to-answer for acutely ill patients where a central-lab turnaround of hours is clinically unacceptable. Excludes central-lab routine panels and complex genomic testing.

Market size
$2.6B
$2.6B ($1.9B–$3.4B) · 2025 · Triangulated
Growth
+9.0%
$4.1B by 2030
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
4 sources · Triangulated
Level
Niche
Segmented by
Customer type
Buyers
Hospital laboratories and acute-care departments, plus specialised diagnostic providers operating urgent-care and ambulatory sites
Buying centre
Hospital emergency/ambulatory operations leadership with clinical microbiology and infection-control sign-off; purchasing run through hospital supply chain or GPO contracts, often with per-test or per-cartridge pricing.
Buying triggers
  • Antimicrobial stewardship and sepsis-pathway targets that require rapid results
  • Hospital-acquired infection and outbreak response protocols
  • Shift of care into urgent care and ambulatory settings
  • Reimbursement for syndromic panels and rapid respiratory testing
Pains
  • High cost per test and cartridge wastage when run at low volume
  • Reimbursement for rapid syndromic panels is inconsistent across payers
  • Workflow and staff training burden of running molecular systems outside the central lab
  • Need for connectivity and result integration with the LIS/EHR
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability—
Growth—

How this was sized

$2.6B ($1.9B–$3.4B) · 2025 · Triangulated

Same USD 22.0B submarket pool as the other niches (see notes in niche 1). Rapid/point-of-care molecular assumed 12% of the submarket = USD 2.64B (range 1.9-3.4B). Forecast: 2,640 x 1.09^5 = USD 4,060M in 2030. 9.0% CAGR reflects faster growth than the 4.78% clinical diagnostics CAGR [1] and the 5.5% CAGR in [9], consistent with the shift of medtech into alternative care settings noted in [2]. Low confidence: no source in the set sizes point-of-care molecular directly; the 12% share is an assumption.

Alongside it in Molecular and specialised diagnostics

// Sell into Rapid and point-of-care molecular testing for acute-care decisions

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.